You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Mesoblast Limited (MSB) develops, manufactures, and commercializes of biological therapies for the emerging field of regenerative medicine. MSB is commercialising patented adult stem cell-based products for large clinical indications such as cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, cartilage degeneration, and musculoskeletal conditions.
Strategy Analysis: MSB is developing a proprietary stem cell technology for the treatment of orthopaedic conditions such as bone fractures, degenerated knee cartilage and vertebral disc degeneration. Through an investment in and subsequent merger with Angioblast Systems, Inc. MSB is also developing stem cell treatments for cardiac and vascular diseases, and other degenerative conditions. MSB's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of pre-clinical and clinical milestones to commercialise the technology. The firm already has TGA approval to manufacture and distribute patient-specific adult stem cell products to hospitals and physicians across Australia; this is the first culture-expanded adult stem cell product to receive manufacturing approval anywhere in the world.
Mesoblast reported a net loss of $27.79m for the half-year ended 31 December 2012 (31 Dec 2011: $17.6m). The increased loss was driven by a reduction in revenue from continuing operations and other income of $4.3m and an increase in expenses from continuing operations of $5.9m. Revenues from ordinary activities were $14.73m, down 22% from the same period last year. Diluted EPS was (9.69) cents compared to (15.52) cents last year. The net operating cash outflow was $30.52m compared to an outflow of $36.89m in the pcp. No dividend was declared. In the second half of the financial year, the Company expects to continue to report on clinical outcomes from a number of Phase 2 programs and to initiate new programs in line with the overall corporate strategy.
The Age 23/05/2013 |
The local sharemarket closed lower for a second consecutive day, dragged down by the banks and a surprisingly poor consumer sentiment report.
The Age 23/05/2013 |
Non-bank lender Resimac has made a bid to acquire the remnants of mortgage firm RAMS in a joint proposal with former Babcock & Brown banker Trevor Loewensohn.
The Age 23/05/2013 |
Department store Myer will switch its focus from relentless cost-cutting to driving sales growth and grabbing a greater slice of the discretionary spend by shoppers.
The Age 23/05/2013 |
Australia's top commodities agency has detailed a year of woe for the local resources industry and joined the Reserve Bank in declaring the peak of investment in the sector.
The Age 23/05/2013 |
Significant job losses are expected at Telstra after the telco announced sweeping changes to its operational structure as it shifts away from its legacy business.
Already a member? 
$ 6.030
